Clinical Trial Update: A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers. [Phase 2]

View source ↗

Summary

Phase 2a randomized study evaluating safety and efficacy of RZL-012 for submental fat reduction has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat

Drugs mentioned

• RZL-012

Snippet

Sponsor: Raziel Therapeutics Ltd. | Conditions: Submental Fat | Phase 2 | Status: COMPLETED | Results posted: 2023-11-18